01—Abstract
Summary
Summary of the 10-Q filed July 31, 2026. Cited figures are marked; the original filing is the authoritative source.
Stryker Corporation reported strong financial results for the second quarter and first half of 2026.
Net sales increased by 9.4% year-over-year for the quarter and 6.1% for the six-month period, driven by robust unit volume growth across both the MedSurg and Neurotechnology, and Orthopaedics segments. This top-line growth translated into significant improvements in profitability. Operating income saw a substantial increase, rising to $1.66 billiona for the quarter and $2.59 billion for the six months, up from $1.11 billion and $1.95 billion in the prior year periods, respectively.
This expansion in operating income, coupled with a higher gross profit margin, led to a significant increase in net earnings, which grew by 44.3% for the quarter to $1.28 billionb and 31.4% for the six months to $2.02 billion. Diluted EPS also saw a considerable jump, reflecting the strong earnings performance.
02—Key points
Key Highlights
- Net sales grew by 9.4% to $6.59 billion for the second quarter of 2026 and 6.1% to $12.61 billion for the first six months, indicating strong market demand and successful product introductions.
- Gross profit margin improved significantly, increasing to 68.3% in Q2 2026 from 63.8% in Q2 2025, driven by cost efficiencies and a favorable reversal of import tariffs.
- Operating income surged by 49.0% year-over-year in the second quarter to $1.66 billion, and by 33.1% for the first six months to $2.59 billion, demonstrating effective cost management and operational leverage.
- Net earnings experienced robust growth, rising 44.3% to $1.28 billion in Q2 2026 and 31.4% to $2.02 billion in the first six months.
- Diluted earnings per share (EPS) increased by 44.1% to $3.30 for the quarter and 31.4% to $5.23 for the six-month period, reflecting the strong bottom-line performance.
- The company completed the acquisition of AVS for $435 million, expanding its Peripheral Vascular business, and continues to focus on its capital allocation strategy prioritizing acquisitions, dividends, and share repurchases.
03—Questions
Frequently Asked Questions
What was the primary driver of Stryker's revenue growth in the second quarter of 2026?
Stryker's revenue growth in the second quarter of 2026 was primarily driven by a 9.0% increase in constant currency sales, attributed to higher unit volumes across most of its MedSurg and Neurotechnology and all Orthopaedics businesses. Foreign currency exchange rates also provided a small positive impact.
How did Stryker's profitability change in the second quarter compared to the prior year?
Stryker's profitability saw significant improvement. Gross profit margin increased to 68.3% from 63.8%, and operating income grew by 49.0% to $1.66 billion. This led to a 44.3% increase in net earnings to $1.28 billion, with diluted EPS rising by 44.1% to $3.30.
What are the key factors contributing to the improvement in gross profit margin?
The improvement in gross profit margin for the second quarter of 2026 was primarily due to a reduction in certain import tariffs and lower amortization of inventory stepped up to fair value. For the six-month period, this was partially offset by higher manufacturing and supply chain costs related to a cybersecurity incident.
Did Stryker make any significant acquisitions during the period?
Yes, in May 2026, Stryker completed the acquisition of AVS for net cash consideration of $435 million, plus potential future milestone payments. AVS is focused on developing intravascular lithotripsy technology for peripheral arterial disease.
04—Continue